Last Price$9.90Cboe Real-Time Last Sale as of 3:29PM ET 8/10/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.57(6.11%)
Bid (Size)$9.89 (124)
Ask (Size)$9.95 (5)
Day Low / High$9.50 - 10.03
Volume58.1 K

MeiraGTx Sees Positive Data From Phase 1/2 Trial of Botaretigene Sparoparvovec for X-Linked Retinitis Pigmentosa Patients

8:11AM ET 6/28/2022 MT Newswires
MeiraGTx Holdings (MGTX) said Tuesday it has seen encouraging data from a phase 1/2 clinical study of botaretigene sparoparvovec to treat patients with X-linked retinitis pigmentosa when compared with untreated randomized control.

The clinical-stage company said treatment with botaretigene sparoparvovec was found to be generally safe and well-tolerated.

The company also said significant improvements were demonstrated in several endpoints across each of the three aspects of retinal function, visual function and functional vision.

More results from the phase 1/2 study will be presented at medical meetings in H2, MeiraGTx said.

Botaretigene sparoparvovec is being jointly developed by MeiraGTx and Janssen Pharmaceuticals, a unit of Johnson & Johnson (JNJ).